Windtree signs a new financing protocol of 520 million USD to strengthen its BNB reserve strategy.

ChainCatcher news, Nasdaq-listed biotechnology company Windtree Therapeutics (WINT) announced that it has signed a common stock purchase agreement of up to $500 million to establish an equity line of credit (ELOC). In addition, the company has also signed an additional stock purchase agreement worth $20 million with Build and Build Corp. The total financing scale reaches up to 520 million dollars, of which 99% of the funds will be used to purchase BNB. The company plans to officially start using the funds after obtaining shareholder approval to increase the authorized number of common stocks.